The three organizations issued a statement saying they oppose ordering, prescribing and dispensing ivermectin to prevent or treat COVID-19 outside the context of a clinical trial.
Bio-Thera will maintain responsibility for development, manufacturing and supply of the biosimilar Stelara while Hikma will have exclusive rights to commercialize the product in the United States.